AMPK activation alleviated dextran sulfate sodium-induced colitis by inhibiting ferroptosis

Shao Peng Sun1, Yi Fan Lu1, Heng Li1

  • 1The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.

Abstract

Insights

Ferroptosis, a cell death pathway, occurs in ulcerative colitis (UC). Activating adenosine monophosphate-activated protein kinase (AMPK) inhibits ferroptosis in colitis, suggesting it as a potential therapeutic target.

Area of Science:

  • Cell biology
  • Gastroenterology
  • Biochemistry

Background:

  • Ferroptosis, a regulated cell death, is implicated in intestinal epithelial cells of ulcerative colitis (UC).
  • Understanding the mechanisms of ferroptosis and its regulators in UC is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of ferroptosis and its association with adenosine monophosphate-activated protein kinase (AMPK) in ulcerative colitis (UC).
  • To explore the therapeutic potential of targeting AMPK in UC-related ferroptosis.

Main Methods:

  • Analysis of colonic gene expression profiles (GSE87473) from UC patients and healthy controls.
  • Utilized human colonic samples and a dextran sodium sulfate (DSS)-induced colitis murine model.
  • Assessed ferroptosis markers (GPX4, FTH1), iron levels, lipid peroxidation, and mitochondrial integrity; evaluated AMPK activation effects using metformin.

Main Results:

  • UC patients and DSS-induced colitis mice exhibited decreased GPX4 and FTH1 expression, increased iron, and lipid peroxidation.
  • Reduced AMPK expression was observed in UC patients, correlating with FTH1 and GPX4 levels.
  • Metformin-induced AMPK activation suppressed ferroptosis, alleviated colitis symptoms, and improved survival in mice.

Conclusions:

  • Ferroptosis is a significant feature in the colonic tissues of UC patients.
  • AMPK activation demonstrates a protective effect against ferroptosis in a murine colitis model.
  • AMPK represents a promising therapeutic target for managing ulcerative colitis.